Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer

Weihua Li1*, Rui Wan2†, Lei Guo1, Geyun Chang2, Dong Jiang3, Lin Meng3 and Jianming Ying1*

Abstract

Background: Diverse genomic breakpoints of fusions that localize to intronic, exonic, or intergenic regions have been identified by DNA next-generation sequencing (NGS), but the role of exonic breakpoints remains elusive. We investigated whether exonic-breakpoint fusions could predict matched targeted therapy efficacy in non-small cell lung cancer (NSCLC).

Methods: NSCLC samples were analyzed by DNA NGS, RNA NGS, immunohistochemistry (IHC), and fluorescence in situ hybridization.

Results: Using DNA NGS, kinase fusions were identified in 685 of 7148 (9.6%) NSCLCs, with 74 harboring exonic-breakpoint fusions, mostly anaplastic lymphoma kinase (ALK) fusions. RNA NGS and IHC revealed that 11 of 55 (20%) exonic-breakpoint fusions generated no aberrant transcript/protein, possibly due to open reading frame disruption or different gene transcriptional orientations. Four cases of genomic-positive but RNA/protein-negative fusions were treated with matched targeted therapy, but progressive disease developed within 2 months. Nevertheless, 44 of 55 (80%) exonic-breakpoint fusions produced chimeric transcripts/proteins, possibly owing to various alternative splicing patterns, including exon skipping, alternative splice site selection, and intron retention. Most of these genomic- and RNA/protein-positive fusion cases showed a clinical response to matched targeted therapy. Particularly, there were no differences in objective response rate ($P = 0.714$) or median progression-free survival ($P = 0.500$) between intronic-breakpoint ($n = 56$) and exonic-breakpoint ALK fusion subtypes ($n = 11$) among ALK RNA/protein-validated patients who received first-line crizotinib.

Conclusions: Exonic-breakpoint fusions may generate in-frame fusion transcripts/proteins or not, and thus are unreliable for predicting the efficacy of targeted therapy, which highlights the necessity of implementing RNA or protein assays for functional validation in exonic-breakpoint fusion cases.

Keywords: Non-small cell lung cancer, DNA sequencing, Exonic-breakpoint fusion, Alternative splicing, Targeted therapy

Background

Targeted therapies, many of which target receptor tyrosine kinases, have been extensively developed to treat patients with non-small cell lung cancer (NSCLC), leading to dramatic improvements in patient survival. Genes
fusions are potent targets of therapy [1, 2]. Some kinase fusions, such as anaplastic lymphoma kinase (ALK), v-ros UR2 sarcoma virus oncogene homolog 1 (ROSI), and rearranged during transfection (RET), have been well characterized in NSCLC, and tyrosine kinase inhibitors (TKIs) have become a standard treatment option for advanced NSCLC patients harboring these fusions [3–6]. Other actionable kinase fusions, including neu-regulin 1 (NRG1), neurotrophic receptor tyrosine kinases (NTRKs), fibroblast growth factor receptors (FGFRs), epidermal growth factor receptor (EGFR), and mesenchymal-epithelial transition factor (MET), are present in a diverse fraction of NSCLCs that are increasingly gaining attention with regard to novel targeted therapy development [7].

Several different methods have been developed for detecting these gene fusions in NSCLC. Among them, genomic DNA-based next-generation sequencing (DNA NGS) has been widely applied in recent years, as it enables comprehensive discovery of various actionable alterations (including mutations, fusions, and copy number variants) in NSCLC [8]. Using DNA NGS, we previously identified diverse genomic breakpoints that occur in intronic, exonic, or intergenic regions in NSCLC [9, 10]. In general, the genomic breakpoints occur at two genetic elements and form aberrant fusions that would produce typically deleterious chimeric fusion transcripts/proteins [11]. Actually, intronic-breakpoint fusions in which both genomic breakpoints localize to intronic regions usually lead to in-frame chimeric fusion transcripts/proteins because the coding sequences are completely preserved [12]. However, intergenic-breakpoint fusions, in which one or both genomic breakpoints are in intergenic regions, may or may not generate functional fusion transcripts, as revealed by RNA sequencing in our previous study and in another study [10, 13]. Fusions involving one or both exonic breakpoints (exonic-breakpoint fusions) in theory have a high chance of resulting in out-frame transcripts/proteins due to coding sequence disruption. Nonetheless, considering the potential unreliability of genomic breakpoints identified by DNA sequencing in predicting breakpoints at the transcript level [9], it is of great importance to determine whether exonic-breakpoint fusions can unequivocally generate in-frame functional fusion transcripts/proteins to accurately select NSCLCs for targeted therapy.

In this study, we systematically characterized the function of exonic-breakpoint fusions in a large number of NSCLC cases through multiplex molecular testing approaches, including DNA NGS, RNA NGS, immuno-histochemistry (IHC), and fluorescence in situ hybridization (FISH). We further explored the association of exonic-breakpoint fusions with the efficacy of matched TKIs to evaluate the reliability of exonic-breakpoint fusions in predicting the benefit of targeted therapy in NSCLC.

Methods
Patients and tumor samples
A total of 7158 samples from 7148 patients with NSCLC who underwent molecular testing in our laboratory between January 2017 and December 2021 were retrospectively included in this study. Relevant clinical data, such as clinicopathological features and treatment history, were obtained from clinical records. The study was approved by the Institutional Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. Written informed consent was obtained from each patient, and the methods were carried out in accordance with approved guidelines.

Isolation of DNA and RNA
Tumor cellularity was evaluated through hematoxylin and eosin (HE)-stained slides by two or more pathologists, as previously described [14]. Tissues with ≥20% tumor cellularity were selected. Genomic DNA was extracted using a QIAamp DNA FFPE Tissue Kit, and RNA was extracted using a Novogene RNA Extraction Kit (Novogene, Tianjin, China). DNA and RNA quantities were measured using a Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Carlsbad, CA, USA) and a NanoDrop ND-1000 Spectrophotometer (NanoDrop, Waltham, MA, USA), and the qualities were determined using an Agilent 2100 Bioanalyzer system (Agilent Technologies Inc. CA, USA).

DNA NGS
Hybrid capture-based targeted DNA NGS was performed using a panel designed against 56 genes, as previously described [10]. Briefly, at least 50 ng of genomic DNA was used to generate sequencing libraries through sequential steps, including DNA fragmentation, PCR amplification, hybridization, and probe capture. Indexed sequencing libraries were sequenced using the Illumina Nextseq N500 platform (Illumina, San Diego, CA, USA), and sequencing data were analyzed with an in-house Molecular Diagnostics Management System to determine alterations such as mutations, copy number variants, and fusions. Fusions were identified by a variant allele frequency (VAF) ≥2% and coverage ≥1000×. All fusions were further manually analyzed by a geneticist to exclude artifactual fusion events owing to misalignment and mispriming, among other factors.
RNA NGS
Hybrid capture-based targeted RNA NGS was performed using the TruSight RNA fusion panel (Novogene, Tianjin, China), consisting of the 95 genes listed in Additional file 1: Table S1. Briefly, 100 ng of total RNA was reverse transcribed using a random primer mix. Synthesized cDNA was end-repaired and then used to generate sequencing libraries according to the manufacturer’s instructions. The enriched libraries were sequenced with the Novaseq 6000 platform (Illumina, San Diego, CA, USA), and sequencing data were further analyzed using an in-house analysis system to identify fusion transcripts, including fusion genes and breakpoints, at the transcript level.

IHC
ALK, ROS1, and RET expression was evaluated by an IHC assay, as previously described [10]. In brief, tissue samples were incubated with a Ventana anti-ALK (D5F3) rabbit monoclonal antibody (Ventana Benchmark XT stainer, Ventana Medical Systems Inc., AZ, USA), an anti-ROS1 (OTI1A1) mouse monoclonal antibody (Zhongshan Golden Bridge Biotechnology, Beijing, China), or an anti-RET (EPR2871) rabbit monoclonal antibody (Abcam, Cambridge, MA, USA) according to the manufacturer’s instructions. Binary scoring system (−, negative; +, positive) was used for evaluating the ALK staining results, and ALK positivity (ALK+) was identified when tumor cells showed strong granular cytoplasmic staining [15]. ROS1 and RET expression was evaluated using the following scoring scheme: −, no staining; 1+, weak staining, 2+, moderate staining, and 3+, strong staining in > 10% of tumor cells.

FISH
FISH assays were carried out to detect ALK and ROS1 fusions at the DNA level. As previously described [15], tumor tissues were sectioned, mounted onto microscope slides, and incubated with Vysis LSI ALK/ROS1 Dual color, Break Apart Rearrangement Probes (Abbott/Vysis, Abbott Park, IL, USA). The slides were evaluated under a fluorescence microscope by two expert pathologists. Positive results were identified as more than 15% of tumor cells with splitting of one or both 5′ and 3′ probe signals or with isolated 3′ probe signals.

Efficacy evaluation of targeted therapy
The clinical responses of advanced NSCLC patients who harbored ALK, ROS1, or RET fusions and had received matched targeted agents were assessed by oncologists based on radiographic imaging. The optimal response, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), was evaluated following the guidelines of Response Evaluation Criteria in Solid Tumors version 1.1 [16]. The cutoff date was December 31, 2021, and data were censored if patients were still alive and showed no progression at the latest follow-up date. The objective response rate (ORR) was defined as the percentage of patients with CR or PR. Progression-free survival (PFS) was calculated from the date of treatment to the date of PD or death from any cause.

Statistical analysis
All data were analyzed using SPSS 22.0 software (Chicago, IL, USA). Differences in clinicopathologic variables between the two groups were investigated by the chi-square test or Fisher’s exact test. PFS was analyzed using the Kaplan-Meier method and log-rank test. A two-sided P < 0.05 was considered statistically significant.

Results
Characteristics of fusion-positive NSCLCs identified by DNA NGS
Tumor tissues from 7148 NSCLC patients were interrogated using DNA NGS. Most of these patients (6615/7148, 89.7%) were diagnosed with adenocarcinoma. The patient characteristics are listed in Additional file 1: Table S2. Kinase fusions, including ALK, ROS1, RET, NRG1, NTRK1, NTRK3, FGFR1, FGFR2, FGFR3, EGF, and MET, were identified in 685 (9.6%) cases. ALK was the most commonly detected fusion gene, followed by RET and ROS1 (Fig. 1A). According to the genome base position of the breakpoint, fusions can be divided into four subtypes: intronic-breakpoint (“intron-intron” fusions), intergenic-breakpoint (“intron-intergenic,” “intergenic-intron,” or “intergenic-intergenic” fusions), exonic-breakpoint (“intron-exon,” “exon-intron,” or “exon-exon” fusions), and mixed-breakpoint fusions (“exon-intergenic” fusions, “intergenic-exon” fusions, or multiple fusions with two or more breakpoint subtypes). Overall, intronic-, intergenic-, exonic-, and mixed-breakpoint fusions were identified in 520 (75.9%), 51 (7.4%), 74 (10.8%), and 40 (5.8%) cases, respectively. The ratio of exonic-breakpoint fusion events was higher for uncommon fusions than for ALK, ROS1, and RET fusions (21.8% vs. 9.8%, P = 0.006, Fig. 1B), although no marked differences in clinicopathological characteristics were found between exonic-breakpoint fusions and other fusion subtypes (Additional file 1: Table S3). Paired samples from the same patient, including paired primary and metastatic tumors (n = 4), paired different metastatic tumors (n = 1), paired tissue and plasma samples (n = 2), and paired
pre- and post-TKI samples \( (n=3) \), showed the same rearrangement involving exonic breakpoint, further supporting the presence of exonic-breakpoint fusions at the DNA level (Additional file 1: Table S4).

**Classification and validation of exonic-breakpoint fusions**

The exonic-breakpoint fusions could be further classified into three categories on the basis of relative genomic locations: (i) “exon-intron” fusions, 39.2% (29/74); (ii) “exon-exon” fusions, 4.1% (3/74); and (iii) “intron-exon” fusions, 56.7% (42/74) (Fig. 1C and Additional file 2: Fig. S1A-C). To verify the function and activity of exonic-breakpoint fusions, RNA NGS and/or IHC were successfully performed in 55 cases with sufficient tissue. Chimeric transcripts/proteins were identified in 44 cases (80%), whereas no expressed fusion transcript/protein was detected in 11 cases (20%, Fig. 1D).

**Possible mechanisms by which exonic-breakpoint fusions generate no aberrant transcript/protein**

Among the 11 cases with genomic-positive but RNA/protein-negative fusions, 4 (P1-P4) harbored “exon-intron” fusions involving \( \text{ALK} \) \( (n=2) \), \( \text{NTRK1} \) \( (n=1) \), or \( \text{FGFR1} \) \( (n=1) \) and 1 (P5) harbored an “exon-exon” \( \text{ROS1} \) fusion (Table 1). Open reading frame disruption in the exonic regions of the 5’ portion may be responsible for these nonproductive rearrangements, as an exon disrupting breakpoint may introduce a premature stop codon that leads to the production of a truncated transcript/protein (Fig. 2A, B). Moreover, the remaining 6 cases (P6-P11) harbored “intron-exon” fusions involving \( \text{ALK} \) \( (n=1) \), \( \text{ROS1} \) \( (n=1) \), \( \text{RET} \) \( (n=1) \), \( \text{FGFR2} \) \( (n=1) \),
All of these specific fusions had a fusion partner that was rare or was never reported (Table 1). Upon manual review in Integrative Genomics Viewer (IGV) [17], we found that the 5′ portion of the kinase genes and the 5′ portion of the partners merged to form “5′-5′ fusions” in 4 cases (P6–P9; Table 1 and Fig. 2C). Similarly, the 3′ portion of the kinase genes and the 3′ portion of the partners merged to form “3′-3′ fusions” in 2 cases (P10–P11; Table 1 and Fig. 2E). The discrepancy between the DNA NGS and RNA NGS/IHC results was likely a result of the formation of antisense rearrangements in which the kinase genes and partners were transcribed in different orientations, resulting in no aberrant transcript/protein (Fig. 2D, F).

Possible mechanisms by which exonic-breakpoint fusions produce functional transcripts/proteins

Among the 44 cases with consistent positive results identified by DNA NGS and RNA NGS/IHC, 19 harbored “exon-intron” fusions involving ALK (n=13), ROS1 (n=3), RET (n=1), NRG1 (n=1), and EGFR (n=1) and 25 harbored “intron-exon” fusions involving ALK (n=16), ROS1 (n=5), and RET (n=4) (Table 2). A manual review of matched DNA and RNA NGS results in IGV was conducted to reveal the possible mechanisms. For P12, with an “exon-intron” fusion (EML4 exon 14-ALK intron 19), DNA NGS indicated the genomic breakpoint in EML4 to be located in the middle region of exon 14, but RNA NGS revealed the breakpoint at the transcript level to be located in exon 13 (Fig. 3A), possibly due to the lack of the 3′ acceptor splice site of the EML4 exon 14 that led to exon skipping (Fig. 3B). Indeed, we found 11 such cases in our cohort (Table 2). Similarly, DNA NGS showed the genomic breakpoint in ALK to be located in the middle region of exon 19 in P23, which harbored an “intron-exon” fusion (EML4 intron 20-ALK exon 19). Nevertheless, exon 19 of ALK was spliced out of the fusion transcript, as revealed by RNA NGS (Fig. 3C). This phenomenon was observed in 12 cases in our cohort, possibly due to exon skipping (Table 2), as the disrupting exon of the 3′ portion lacked a 5′ donor splice site (Fig. 3D). In particular, primary/reciprocal ROS1 fusions were identified by DNA NGS in P26; the reciprocal ROS1 fusion (ROS1-CLK1) was also detected by RNA NGS, although its biological impact on cellular function remained to be confirmed (Table 2). Moreover, uncommon ALK fusions were detected in both P35 and P36 (P35: C2orf91 exon 4-ALK intron 19; P36: CLHC1 intron 4-ALK exon 19; Table 2) by DNA NGS, but the canonical EML4-ALK fusion transcript was identified in these two cases (Additional file 2: Fig. S2A and C). This indicates the involvement of complex rearrangements constituting multiple fusion junctions and rare genes at the DNA level. Nevertheless, these rare genes, even though they showed different transcriptional orientations from the kinase genes (P36), were spliced out during transcription (Additional file 2: Fig. S2B and D).

In addition, a rearrangement of SLC34A2 exon 13-ROS1 intron 33 was detected at the DNA level in P37, and RNA NGS revealed that the breakpoint at the transcript level was in SLC34A2 exon 13, upstream of the predicted breakpoint detected by DNA NGS.
Alternative donor site selection involving a cryptic splice site located within exon 13 of SLC34A2 might have contributed to the formation of an in-frame fusion transcript (Fig. 3F). In P38, the EML4 intron 6-ALK exon 20 rearrangement detected at the DNA level also produced an EML4 intron 6-ALK exon 20 fusion transcript (Fig. 3G and Table 2). The same breakpoint location was observed between matched DNA NGS and RNA NGS results, probably due to intron retention that the intron sequence was integrated into the transcript (Fig. 3H).

Clinical outcomes of targeted therapy in patients with exonic-breakpoint fusions
Four patients with genomic-positive but RNA/protein-negative ALK or ROS1 fusions received targeted agents (crizotinib or alectinib) as first-line treatment, but showed PD within 2 months because no expressed fusion
Table 2  Consistent results observed at the DNA and RNA/protein levels in patients with exonic-breakpoint fusions

| Case | Sex | Age | Diagnosis | DNA NGS | Other variants | RNA NGS | FISH | IHC |
|------|-----|-----|-----------|---------|----------------|---------|------|-----|
|      |     |     |           | Fusion  |                |         |      |     |
| Exon skipping (5’ gene) | | | | | | | | |
| P12  | F  | 63  | ADC       | EML4-ALK (exon 14: intron 19) | TP53 p.E171K | EML4-ALK (exon 13: exon 20) | N/A   | +   |
| P13  | M  | 57  | ADC       | EML4-ALK (exon 14: intron 19) | None          | EML4-ALK (exon 13: exon 20) | N/A   | +   |
| P14  | F  | 35  | ADC       | EML4-ALK (exon 21: intron 19) | None          | EML4-ALK (exon 20: exon 20) | N/A   | +   |
| P15  | F  | 69  | ADC       | EML4-ALK (exon 14: intron 19) | None          | EML4-ALK (exon 13: exon 20) | N/A   | +   |
| P16  | F  | 44  | ADC       | EML4-ALK (exon 21: intron 19) | None          | EML4-ALK (exon 20: exon 20) | N/A   | +   |
| P17  | F  | 58  | ADC       | EML4-ALK (exon 21: intron 19) | P16N p.E99*   | EML4-ALK (exon 20: exon 20) | N/A   | +   |
| P18  | F  | 66  | ADC       | CD74-ROS1 (exon 7: intron 33) | TP53 p.R442fs | CD74-ROS1 (exon 6: exon 34) | N/A   | 3+  |
| P19  | F  | 72  | ADC       | TPM3-ROS1 (3’UTR: intron 34) | None          | TPM3-ROS1 (exon 6: exon 35) | N/A   | 1+  |
| P20  | F  | 64  | ADC       | KIF5B-RET (exon 17: intron 11) | TP53 p.I323S | KIF5B-RET (exon 16: exon 12) | N/A   | 3+  |
| P21  | F  | 70  | ADC       | CD74-NRG1 (exon 7: intron 5) | None          | CD74-NRG1 (exon 6: exon 6)  | N/A   | N/A |
| P22  | M  | 55  | ADC       | SGRF-BCAR4 (exon 27: intron 2) | None          | SGRF-BCAR4 (exon 26: exon 3) | N/A   | N/A |
| Exon skipping (3’ gene) | | | | | | | | |
| P23  | M  | 63  | ADC       | EML4-ALK (exon 20: exon 19) | None          | EML4-ALK (exon 20: exon 20) | N/A   | +   |
| P24  | M  | 70  | ADC       | EML4-ALK (intron 6: exon 18) | None          | EML4-ALK (exon 6: exon 20); EML4-ALK (intron 6: exon 20) | N/A   | +   |
| P25  | F  | 63  | ADC       | EML4-ALK (exon 6: exon 19) | None          | EML4-ALK (exon 6: exon 20) | N/A   | +   |
| P26  | F  | 72  | ADC       | CD74-ROS1 (exon 6: exon 32); ROS1-CLK1 | None | CD74-ROS1 (exon 6: exon 34); ROS1-CLK1 | N/A | 1+  |
|      |     |     |           |         |                |         |      |     |
| Exon skipping in complex rearrangements | | | | | | | | |
| P35  | M  | 59  | ADC       | C2orf91-ALK (exon 4: intron 19) | None          | EML4-ALK (exon 20: exon 20) | N/A   | N/A |
| P36  | M  | 57  | ADC       | CLEC1-ALK (intron 4: exon 19) | None          | EML4-ALK (exon 13: exon 20) | N/A   | +   |
| Alternative 5’ splice site | | | | | | | | |
| P37  | F  | 60  | ADC       | SLC34A2-ROS1 (exon 13: exon 33) | None          | SLC34A2-ROS1 (exon 13: exon 34) | N/A   | 3+  |
| Intron retention | | | | | | | | |
| P38  | M  | 76  | ADC       | EML4-ALK (intron 6: exon 20) | None          | EML4-ALK (intron 6: exon 20) | N/A   | +   |
| Unknown mechanisms | | | | | | | | |
| P39  | F  | 50  | ADC       | EML4-ALK (exon 21: intron 19) | None          | None | N/A | +   |
| P40  | M  | 54  | ADC       | EML4-ALK (exon 14: intron 19) | None          | None | N/A | +   |
| P41  | M  | 55  | ADC       | EML4-ALK (exon 21: intron 19) | CDKN2A p.E26fs; NF1 p.D618fs | None | N/A | +   |
| P42  | F  | 66  | ADC       | EML4-ALK (exon 14: intron 19) | None          | None | N/A | +   |
| P43  | F  | 26  | ADC       | PCARE-ALK (exon: intron 19) | None          | None | N/A | +   |
| P44  | M  | 64  | ADC       | EML4-ALK (exon 14: intron 19) | None          | None | N/A | +   |
| P45  | M  | 70  | ADC       | KIF5B-ALK (exon 20: exon 20) | TP53 p.E286K | None | N/A | +   |
| P46  | F  | 51  | ADC       | PPT1CB-ALK (intron 4: exon 20) | None          | None | N/A | +   |
| P47  | F  | 45  | ADC       | EML4-ALK (exon 6: exon 19) | None          | None | N/A | +   |
| P48  | F  | 65  | ADC       | KIF5B-ALK (exon 15: exon 20) | TP53 p.E171K | None | N/A | +   |
| P49  | F  | 63  | ADC       | EML4-ALK (exon 6: exon 19) | None          | None | N/A | +   |
| P50  | M  | 41  | ADC       | FARS2-ALK (exon: intron 19) | None          | None | N/A | +   |
| P51  | M  | 59  | ADC       | PICALM-ALK (exon 19: exon 20) | None          | None | N/A | +   |
| P52  | M  | 33  | ADC       | EML4-ALK (exon 4: exon 19) | None          | None | N/A | +   |
| P53  | F  | 63  | ADC       | EML4-ALK (exon 6: exon 17) | None          | None | N/A | +   |
| P54  | F  | 69  | ADC       | EML4-ALK (exon 19: exon 20) | None          | None | N/A | +   |
| P55  | M  | 34  | ADC       | EML4-ALK (exon 14: exon 20) | TP53 p.E171K | None | N/A | +   |

F Female, M Male, ADC Adenocarcinoma, LCNEC Large cell neuroendocrine carcinoma, N/A Not available, NGS Next-generation sequencing, FISH Fluorescence in situ hybridization, IHC Immunohistochemistry, + positive, 1+ weak staining, 2+ moderate staining, 3+ strong staining
transcript/protein was produced (Fig. 4A). Among those with genomic- and RNA/protein-positive fusions, 19 received a matched targeted therapy, including agents against ALK (n=15), ROSI (n=2), and RET (n=2), and almost all of them benefited from this treatment (Additional file 1: Table S5). Among them, 11 patients harboring exonic-breakpoint ALK fusions who received crizotinib as a first-line treatment were further analyzed, together with 56 harboring intronic-breakpoint ALK fusions. All these cases were confirmed to be ALK positive by RNA NGS or IHC, and there were no marked differences in the baseline features of the two groups (Additional file 1: Table S6). Compared with patients harboring intronic-breakpoint ALK fusions, those harboring exonic-breakpoint ALK fusions exhibited no difference in the ORR (76.8%, 95% CI: 64.2–85.9% vs. 81.8%, 95% CI: 52.3–94.9%, P = 0.714; Additional file 1: Table S7). Moreover, no difference in median PFS was observed between patients with intronic-breakpoint ALK fusions (13.1 months, 95% CI: 11.5–14.8) and those with exonic-breakpoint ALK fusions (15.0 months, 95% CI: 11.6–18.4, P=0.500, Fig. 4B). Additionally, although no validation assays were available for the 19 patients harboring exonic-breakpoint fusions, 4 with ALK or ROSI fusions treated with crizotinib or alectinib showed a durable response (10.1–23.8 months, Additional file 1: Table S5), strongly suggesting the presence of active fusion events in these 4 cases. However, two patients with exonic-breakpoint ROSI fusions failed to respond to crizotinib therapy, indicating that the fusion events in these 2 cases may have been silenced with no detectable transcript or clinical relevance.

**Discussion**

NGS has greatly improved the molecular diagnosis of cancer patients harboring diverse genetic aberrations [18]. With DNA mutations such as those in EGFR and Kirsten rat sarcoma viral oncogene homolog (KRAS) constituting a major percentage of Chinese NSCLC cases, DNA NGS is the first choice for patients who have never undergone genetic testing. However, in previous studies, we found that the capability of DNA NGS in identifying and characterizing fusion events is limited, especially when uncommon fusions are concerned [9, 10]. In the present study, through a systematic comparison of DNA NGS results with RNA NGS/IHC results, as well as analyses of matched targeted therapy efficacy, we found fusions involving exonic breakpoints to be difficult to interpret only from DNA sequencing data, as functional fusion transcripts/proteins may or may not be produced, thus confounding the oncologists in decision-making for treatment prioritization.

The genomic breakpoints of fusions usually occur in intronic regions, possibly because for most genes, introns are much longer than exons [19]. Despite this bias for intronic breakpoints, exonic breakpoints have been reported in some fusions, including ALK, ROSI, and FGFRs [20–23]. However, the characteristics and functions of exonic-breakpoint fusions in NSCLC remain largely unknown. In our study, intronic-breakpoint fusions constituted a large portion (75.9%) of our cohort of fusion-positive NSCLC patients, and exonic-breakpoint fusions comprised only 7.4%. Intronic-breakpoint fusions are usually transcribed into in-frame fusion transcripts because the coding sequences are rarely disrupted [9]. However, up to 20% (11/55) of exonic-breakpoint fusions in our study were nonproductive. Exonic breakpoints can occur in the 5′ or 3′ portion of a gene or in both, leading to the formation of “exon-intron,” “intron-exon,” or “exon-exon” fusions. Notably, breakpoints that occur in the exon of the 5′ portion of a gene have a high chance (two-in-three chance) of disrupting the coding sequence, thus introducing a premature stop codon and generating a nontranslated transcript. However, for fusions that disrupt an exon in the 3′ portion of a gene, nonproductive rearrangements are formed mainly because the two merged genes are in different transcriptional orientations. These antisense rearrangements can

---

**Fig. 3** Examples and schematic diagrams of exonic-breakpoint fusions generating functional transcripts. A In P12, DNA NGS detected an exonic-breakpoint ALK fusion involving EML4 exon 14 and ALK intron 19, whereas RNA NGS revealed an ALK fusion involving EML4 exon 13 and ALK exon 20. B Schematic diagram showing that the breakpoint at the transcript level differs from that predicted by the genomic breakpoint in the “exon-intron” fusion due to exon skipping. C In P23, DNA NGS showed an exonic-breakpoint ALK fusion involving EML4 exon 20 and ALK exon 19, whereas RNA NGS detected an ALK fusion involving EML4 exon 20 and ALK exon 20. D Schematic diagram showing that the breakpoint at the transcript level differs from that predicted by the genomic breakpoint in the “intron-exon” fusion due to exon skipping. E In P37, DNA NGS showed an exonic-breakpoint ROSI fusion involving SLC34A2 exon 13 and ROSI intron 33, and RNA NGS revealed a ROSI fusion involving SLC34A2 exon 13 and ROSI exon 34. F Schematic diagram showing that the breakpoint at the transcript level differs from that predicted by the genomic breakpoint due to alternative splicing site selection. G In P38, DNA NGS detected an exonic-breakpoint ALK fusion involving EML4 intron 6 and ALK exon 20, whereas RNA NGS revealed an ALK fusion involving EML4 intron 6 and ALK exon 20. H Schematic diagram showing that the breakpoint at the transcript level differs from that predicted by the genomic breakpoint due to intron retention. The gray bars indicate sequencing reads that match the reference genome, and multicolored bars indicate mismatched reads (the corresponding partners). The rectangles indicate exons (E, exon), and the solid lines indicate introns. The arrows indicate the direction of transcription.
Fig. 3 (See legend on previous page.)
also be detected in intronic-breakpoint fusion events, and in this and other studies, all these antisense rearrangements have a rare partner \[24\]. Thus, a novel rearrangement identified by DNA sequencing potentially requires knowledge of the transcriptional orientation of the respective gene, and it is best to perform a confirmatory RNA or protein assay to validate the results.

The fate of an exonic-breakpoint fusion to be transcribed (or not) into aberrant transcripts may be regulated by multiple mechanisms. Alternative splicing may constitute an important biological process that contributes to the production of in-frame fusion transcripts from exonic-breakpoint fusions; indeed, in our study, the genomic breakpoint position did not logically predict the breakpoint position at the transcript level in all RNA-confirmed cases. Alternative splicing is a critical posttranscriptional regulatory mechanism in many types of cancer, and five major forms of alternative splicing have been defined: exon skipping, intron retention, mutually exclusive exons, alternative 5′ splice sites, and alternative 3′ splice sites \[25, 26\]. Exon skipping is the most common alternative splicing event in humans, followed by alternative 5′ donor and 3′ acceptor site selection and intron retention \[27\]. Through comparison of matched DNA and RNA NGS results, we found that 92.6% (25/27) of exonic-breakpoint fusions generated in-frame fusion transcripts due to exon skipping. In particular, genomic fusion partners identified by DNA NGS were uncommon genes, but the fusion partner at the RNA level was EML4 in P35 and P36. One likely cause of such an event is chromothripsis involving many small fragments colocalized to a confined genomic region \[28\]. However, regions of uncommon genes are removed during transcription. In P37, one exonic-breakpoint ROS1 fusion generated an in-frame fusion transcript, possibly because of alternative donor site selection. This splicing process has also been reported in a recent study, in which concurrent EML4-ALK v3a and v3b variants are detected in EML4-ALK v3 NSCLC \[29\]. Moreover, the same position was observed between the genomic breakpoint and breakpoint at the transcript level in P38, which led to a novel EML4-ALK variant, possibly owing to intron retention in which the disrupting intron of EML4 and disrupting exon of ALK were both retained in the chimeric fusion transcript.

Fusion genes drive cancer cell growth and survival mainly through the formation of deleterious chimeric proteins. Several TKIs have been developed to target the kinase domain of these chimeric proteins \[30\]. Theoretically, nonproductive rearrangements involving
exonic breakpoints do not respond well to a matched targeted therapy, but clinical validation is needed. In this study, patients with genomic-positive but RNA/protein-negative fusions who received a relevant targeted therapy showed poor clinical outcomes. However, when genomic- and RNA/protein-positive cases were analyzed, a high ORR and long-term median PFS were observed. In particular, similar ORRs and median PFS were found between patients with exonic-breakpoint ALK fusions and those with intronic-breakpoint ALK fusions when ALK RNA- or protein-validated patients who received first-line crizotinib were analyzed. These data further confirm the potential inaccuracy and unreliability of exonic-breakpoint fusions in predicting the relevant biological outcomes of targeted therapy. Notably, in contrast to constitutive splicing that removes introns and ligates consecutive exons to form expressed fusion transcripts from intronic-breakpoint fusions, alternative splicing may be responsible for generating functional fusion transcripts from exonic-breakpoint fusions. Thus, agents targeting alternative splicing combined with matched TKIs may add value for NSCLC patients harboring RNA/protein-confirmed exonic-breakpoint fusions, which may be a promising research direction for further studies [31].

Our study had some limitations. First, although simultaneous DNA and RNA NGS may accurately illustrate the results of exonic-breakpoint fusions and reveal underlying mechanisms, the instability of RNA is the main drawback for RNA NGS [32]. Second, the clinical relevance of exonic-breakpoint fusions with targeted therapy was explored mainly on the basis of crizotinib in a relatively small number of cases. Future studies involving newer generations of TKIs and a larger population are needed to validate the conclusion.

Conclusions

Our study demonstrates that exonic-breakpoint fusions identified by DNA NGS might be unable to produce fusion transcripts/proteins due to open reading frame disruption or different fusion gene transcriptional orientations, or might produce functional fusion transcripts/proteins owing to alternative splicing. Therefore, when fusions involving exonic breakpoints detected by DNA sequencing occur in the clinic, combined detection of RNA or protein should be implemented to confirm the existence of in-frame functional fusions.

Abbreviations

ALK: Anaplastic lymphoma kinase; CR: Complete response; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; FISH: Fluorescence in situ hybridization; HE: Hematoxylin and eosin; IGV: Integrative Genomics Viewer; IHC: Immunohistochemistry; KRAS: Kirsten rat sarcoma viral oncogene homolog; MET: Mesenchymal-epithelial transition factor; NGS: Next-generation sequencing; NRG1: Neuregulin 1; NSCLC: Non-small cell lung cancer; NTRK: Neurotrophic receptor tyrosine kinase; ORR: Objective response rate; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; RET: Rearranged during transfection; ROS1: V-ros UR2 sarcoma virus oncogene homolog 1; SD: Stable disease; TKI: Tyrosine kinase inhibitor; VAF: Variant allele frequency.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02362-9.

Acknowledgements

None.

Authors' contributions

WL and JY designed the study. WL, RW, and JY wrote and revised the manuscript. WL, RW, and LG obtained patient consent and collected the tissue samples. WL and JY performed the pathology reviews. WL, LG, DJ, and LM prepared samples and performed the experiments. WL, RW, and GC performed the statistical analyses. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of the People’s Republic of China (81972808) and the Beijing Hope Run Special Fund of Cancer Foundation of the People’s Republic of China (LC2019LD04).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical.
References

1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://www.ncbi.nlm.nih.gov/pubmed/27574741.

2. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23(1):277–38. e3. https://www.ncbi.nlm.nih.gov/pubmed/29617662.

3. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94. https://www.ncbi.nlm.nih.gov/pubmed/23724913.

4. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71. https://www.ncbi.nlm.nih.gov/pubmed/25264305.

5. Gainor JF, Cutigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multicohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959–69. https://www.ncbi.nlm.nih.gov/pubmed/34118197.

6. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Sood RA, et al. Continuation of lorlatinib in ALK-positive NSCLC beyond progressive disease. J Thorac Oncol. 2020. https://www.ncbi.nlm.nih.gov/pubmed/32026476.

7. Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res. 2017;6(5):550–9. https://www.ncbi.nlm.nih.gov/pubmed/29114471.

8. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–80. https://www.ncbi.nlm.nih.gov/pubmed/30325992.

9. Li W, Guo L, Liu Y, Dong L, Yang L, Chen L, et al. Potential unreliability of cancer genes by recurrent intergenic fusions. Genome Biol. 2020;21(1):16. https://www.ncbi.nlm.nih.gov/pubmed/32613191.

10. Li W, Qu T, Ling Y, Gao S, Ying J. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing challenges and possible solutions. Mol Oncol. 2018;12(5):677–89. https://www.ncbi.nlm.nih.gov/pubmed/29518290.

11. Ying J, Guo L, Qu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24(10):2589–93. https://www.ncbi.nlm.nih.gov/pubmed/23904459.

12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://www.ncbi.nlm.nih.gov/pubmed/19097774.

13. Torl T, Campo E, Pohlan B, Hsi E. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol. 2004;35(8):1038–41. https://www.ncbi.nlm.nih.gov/pubmed/15297972.

14. Davies KD, Le AT, Sheen J, NJinneh H, Gowan K, Jones KL, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13(10):1474–82. https://www.ncbi.nlm.nih.gov/pubmed/29935306.

15. Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schroock AB, et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol. 2019;14(1):54–62. https://www.ncbi.nlm.nih.gov/pubmed/32329836.

16. Lindeman NI, Tagle PT, Alcerreca ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323–58. https://www.ncbi.nlm.nih.gov/pubmed/29396253.

17. Park BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes mIR-99a regulation in glioblastoma. J Clin Invest. 2013;123(2):855–66. https://www.ncbi.nlm.nih.gov/pubmed/23298836.

18. Tort F, Campo E, Pohlan B, Hsi E. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol. 2004;35(8):1038–41. https://www.ncbi.nlm.nih.gov/pubmed/15297972.

19. Davies KD, Le AT, Sheen J, NJinneh H, Gowan K, Jones KL, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13(10):1474–82. https://www.ncbi.nlm.nih.gov/pubmed/29935306.

20. Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schroock AB, et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol. 2019;14(1):54–62. https://www.ncbi.nlm.nih.gov/pubmed/32329836.

21. Tort F, Campo E, Pohlan B, Hsi E. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum Pathol. 2004;35(8):1038–41. https://www.ncbi.nlm.nih.gov/pubmed/15297972.

22. Davies KD, Le AT, Sheen J, NJinneh H, Gowan K, Jones KL, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13(10):1474–82. https://www.ncbi.nlm.nih.gov/pubmed/29935306.

23. Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schroock AB, et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol. 2019;14(1):54–62. https://www.ncbi.nlm.nih.gov/pubmed/32329836.

24. Rosenthal JM, Bloom R, Forsys JT, Hikken J, Armstrong JR, Branson J, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31(5):791–808. https://www.ncbi.nlm.nih.gov/pubmed/29327716.

25. Kahles A, Lehmann KV, Toussaint NC, Huser M, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34(2):211–24 e6. https://www.ncbi.nlm.nih.gov/pubmed/30078747.

26. Bonnal SC, Lopez-Oreja J, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2017;14(8):457–74. https://www.ncbi.nlm.nih.gov/pubmed/28237072.

27. Schrier S, Lynch KW. Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome. Genes Dev. 2020;34(15-16):1005–16. https://www.ncbi.nlm.nih.gov/pubmed/32744777.

28. Kodama T, Motoi N, Ninomiya H, Sakamoto H, Kitada K, Tsukaguchi T, et al. A novel mechanism of EML4-ALK rearrangement mediated by chromothriposis in a patient-derived cell line. J Thorac Oncol. 2014;9(11):1638–46. https://www.ncbi.nlm.nih.gov/pubmed/25144424.

29. Song Z, Lian S, Mak S, Chow MZ, Xu C, Wang W, et al. Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged NSCLC. J Thorac Oncol. 2021. https://www.ncbi.nlm.nih.gov/pubmed/34626839.

30. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl 8):vii23–30. https://www.ncbi.nlm.nih.gov/pubmed/31738426.
31. Nagasaka M, Ou SI. Targeting alternative splicing as adjunctive treatment in EML4-ALK v3a/b+ NSCLC: knowing our Socratic paradox and learning from spinal muscular atrophy. J Thorac Oncol. 2022;17(2):182–5.

32. Cohen D, Hondelink LM, Solleveld-Westerink N, Uijee SM, Ruano D, Cleon-Jansen AM, et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol. 2020;15(6):1000–14. https://www.ncbi.nlm.nih.gov/pubmed/32014610.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.